Search results for "Coronavirus"
Azelastine nasal spray may prevent COVID-19, trial finds
In a phase 2 industry trial of healthy, vaccinated patients tested twice a week for SARS-CoV-2, thrice-daily intranasal azelastine reduced the COVID-19 infection rate by 67% compared with placebo. Rhinovirus infections were also reduced.
https://immattersacp.org/weekly/archives/2025/09/09/1.htm
9 Sep 2025
AHA scientific statement offers recommendations on exercise for ‘long COVID’
The American Heart Association (AHA) recommended that patients with postacute sequelae of SARS-CoV-2 start with low-duration, low-intensity exercise in a recumbent or semirecumbent position.
https://immattersacp.org/weekly/archives/2025/07/08/4.htm
8 Jul 2025
Nirmatrelvir-ritonavir, remdesivir probably reduce hospitalizations in nonsevere COVID-19
A new systematic review from The BMJ gathered trials in which patients with mild or moderate COVID-19 were randomized to drug treatment versus standard care or placebo to see which medications reduced hospitalization risk or shortened symptoms.
https://immattersacp.org/weekly/archives/2025/06/03/2.htm
3 Jun 2025
No tested biomarkers successfully identified postacute sequelae of SARS-CoV-2
The RECOVER study compared 25 biomarkers in patients who had no lingering symptoms of COVID-19 and those who had at least 12 postacute sequelae symptoms and found no significant differences between the groups.
https://immattersacp.org/weekly/archives/2024/08/13/4.htm
13 Aug 2024
Latest COVID-19 research focuses on PASC, prophylaxis, pregnancy
Postacute sequelae of COVID-19 (PASC) rates dropped with recent variants, one study showed, while an industry trial of postexposure prophylaxis found no effect, and a third study found no risk of congenital anomalies associated with infection or vaccination in the first trimester of pregnancy.
https://immattersacp.org/weekly/archives/2024/07/23/4.htm
23 Jul 2024
COVID-19 vaccine side effects associated with greater antibody response, study finds
The association between worse symptoms after vaccination and higher antibody levels against SARS-CoV-2 in subsequent months could be used to encourage reluctant patients to be vaccinated, study authors suggested.
https://immattersacp.org/weekly/archives/2024/06/11/2.htm
11 Jun 2024
New COVID-19 vaccine recommendations, data on after-effects of infection
The CDC recommended another COVID-19 booster for older patients and ended five-day isolation guidelines, while studies showed that COVID-19 infection was associated with a small cognitive decline and an increase in risk for autoimmune inflammatory rheumatic diseases.
https://immattersacp.org/weekly/archives/2024/03/05/4.htm
5 Mar 2024
One-fifth of COVID-19 patients taking nirmatrelvir-ritonavir had viral rebound
A small observational study of ambulatory patients with COVID-19 found that 1.8% of untreated patients tested positive again after testing negative, compared to 20.8% of those who took five days of nirmatrelvir-ritonavir.
https://immattersacp.org/weekly/archives/2023/11/14/4.htm
14 Nov 2023
Latest COVID-19 studies show need for repeat rapid testing, targeting of antiviral prescriptions
Viral load of SARS-CoV-2 doesn't peak until the fourth day of symptoms, one study found, while other research only saw an effect of nirmatrelvir/ritonavir on death and hospitalization among those who were moderately or severely immunocompromised, not in other high-risk groups.
https://immattersacp.org/weekly/archives/2023/10/03/2.htm
3 Oct 2023
CDC recommends COVID-19 booster; ACP updates practice points for outpatient treatment
Everyone ages 6 months and older should get an updated COVID-19 vaccine to protect against a potentially serious outbreak this fall and winter, the CDC said last week.
https://immattersacp.org/weekly/archives/2023/09/19/1.htm
19 Sep 2023
PASC defined, analyzed by latest COVID-19 studies
Two recent studies focused on postacute sequelae of SARS-CoV-2 (PASC), while another assessed the effectiveness of nirmatrelvir-ritonavir and molnupiravir in reducing morbidity and mortality from COVID-19.
https://immattersacp.org/weekly/archives/2023/06/06/2.htm
6 Jun 2023
ACP, Annals of Internal Medicine host forum on the end of the COVID-19 Public Health Emergency
A full recording of “COVID-19 Is No Longer a Public Health Emergency: Implications for Patients and Clinicians” is available online.
https://immattersacp.org/weekly/archives/2023/05/23/6.htm
23 May 2023
CBT improved severe fatigue after COVID-19, Dutch trial finds
After randomization, patients with severe fatigue three to 12 months after COVID-19 infection benefited from cognitive behavioral therapy (CBT) compared to usual care.
https://immattersacp.org/weekly/archives/2023/05/16/2.htm
16 May 2023
Register now for ACP and Annals of Internal Medicine's forum on the end of the COVID-19 Public Health Emergency
The virtual live event will be held on May 19 from 3:30 to 5 p.m. ET.
https://immattersacp.org/weekly/archives/2023/05/09/5.htm
9 May 2023
Studies look at effectiveness of bivalent booster, fluvoxamine plus inhaled budesonide for COVID-19
After four weeks, bivalent booster vaccines were 47.5% effective against hospitalization or death from COVID-19, a study in North Carolina found, while a Brazilian trial showed that fluvoxamine plus inhaled budesonide significantly reduced the risk of progression to severe disease among high-risk patients with symptomatic COVID-19.
https://immattersacp.org/weekly/archives/2023/04/18/2.htm
18 Apr 2023
COVID-19 rebound occurs with or without antivirals, doesn't affect outcomes, studies find
Rebound of both COVID-19 symptoms and viral load was rare in untreated, unvaccinated outpatients, one study showed, while another found similar rates of viral rebound in patients treated with nirmatrelvir-ritonavir, molnupiravir, or neither antiviral.
https://immattersacp.org/weekly/archives/2023/02/21/2.htm
21 Feb 2023
CDC and FDA weigh in on safety of bivalent vaccine; research examines COVID-19 sequelae, omicron variants
The CDC and FDA said an observed association of ischemic stroke with the Pfizer-BioNTech bivalent booster is very unlikely to represent a true clinical risk. New studies reported on symptoms a year after mild COVID-19 and estimated protection against the omicron variants.
https://immattersacp.org/weekly/archives/2023/01/24/2.htm
24 Jan 2023
New ACP living practice points, mortality data on COVID-19
The College offered recommendations on outpatient COVID-19 treatments. Three studies looked at shifts in mortality from COVID-19 at different times and places. An international study compared infections in health care workers with medical masks versus N95s.
https://immattersacp.org/weekly/archives/2022/11/29/2.htm
29 Nov 2022
Monoclonal antibodies appear safe as COVID-19 treatment during pregnancy
Pregnant patients who received monoclonal antibody treatments had no higher risk for adverse obstetric events but also no significant improvement on COVID-19-related outcomes, a retrospective study found.
https://immattersacp.org/weekly/archives/2022/11/15/2.htm
15 Nov 2022
Frequency of COVID-19 rebound debated in research, ACP/Annals forum
Two letters reported on SARS-CoV-2 viral rebound among patients taking nirmatrelvir-ritonavir. The latest ACP and Annals of Internal Medicine forum brought experts together to discuss this and other clinical challenges in COVID-19 prevention and management on Wednesday, Sept. 7.
https://immattersacp.org/weekly/archives/2022/09/13/2.htm
13 Sep 2022